How do we safely get people to stop smoking?

Cancer Prevention Research

Volumn 4, Issue 11, 2011, Pages 1724-1727

  Lam, David C L ^a   Minna, John D ^b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; AMFEBUTAMONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINE; NICOTINE VACCINE; NICOTINIC RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE P60; VARENICLINE;

APOPTOSIS; CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CANCER RISK; CELL SURVIVAL; DEPRESSION; FOOD AND DRUG ADMINISTRATION; GENETIC ASSOCIATION; HEALTH EDUCATION; HUMAN; LONG TERM CARE; LUNG ALVEOLUS EPITHELIUM; LUNG CANCER; LUNG CARCINOGENESIS; NICOTINE REPLACEMENT THERAPY; NONHUMAN; OVERALL SURVIVAL; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PUBLIC HEALTH; RECEPTOR UPREGULATION; RELAPSE; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SMOKING CESSATION; SUICIDAL IDEATION; TOBACCO DEPENDENCE;

ADENOCARCINOMA; ADENOMA; ANIMALS; CARCINOGENS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; NICOTINE; NITROSAMINES; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 81555195424     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0449     Document Type: Review

References (39)

1. Thun MJ, Henley SJ, Calle EE. Tobacco use and cancer: an epidemiologic perspective for geneticists. Oncogene 2002;21:7307-25. (Pubitemid 35314509)
2. McNeil JJ, Piccenna L, Ioannides-Demos LL. Smoking cessation-recent advances. Cardiovasc Drugs Ther 2010;24:359-67.
3. Cokkinides V, Bandi P, Ward E, Jemal A, Thun M. Progress and opportunities in tobacco control. CA Cancer J Clin 2006;56:135-42. (Pubitemid 43847924)
4. Ziedonis D, Haberstroh S, Hanos Zimmermann M, Miceli M, Foulds J. Adolescent tobacco use and dependence: assessment and treatment strategies. Adolesc Med Clin 2006;17:381-410. (Pubitemid 43949570)
5. Mao JT, Roth MD, Fishbein MC, Aberle DR, Zhang ZF, Rao JY, et al. Lung cancer chemoprevention with celecoxib in former smokers. Cancer Prev Res 2011;4:984-93.
6. Keith RL, Blatchford PJ, Kittelson J, Minna JD, Kelly K, Massion PP, et al. Oral iloprost improves endobronchial dysplasia in former smokers. Cancer Prev Res 2011;4:793-802.
7. Land SR, Cronin WM, Wickerham DL, Costantino JP, Christian NJ, Klein WM, et al. Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the national surgical adjuvant breast and bowel project p-1 breast cancer prevention trial. Cancer Prev Res 2011;4:1393-400.
8. Gritz ER, Dresler C, Sarna L. Smoking, the missing drug interaction in clinical trials: ignoring the obvious. Cancer Epidemiol Biomarkers Prev 2005;14:2287-93. (Pubitemid 41437826)
9. Foulds J, Burke M, Steinberg M, Williams JM, Ziedonis DM. Advances in pharmacotherapy for tobacco dependence. Expert Opin Emerg Drugs 2004;9:39-53. (Pubitemid 38715577)
10. Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008:CD000146.
11. Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer 2003;3:733-44. (Pubitemid 37328812)
12. Tsurutani J, Castillo SS, Brognard J, Granville CA, Zhang C, Gills JJ, et al. Tobacco components stimulate Akt-dependent proliferation and NFkappaB-dependent survival in lung cancer cells. Carcinogenesis 2005;26:1182-95. (Pubitemid 41417895)
13. West KA, Brognard J, Clark AS, Linnoila IR, Yang X, Swain SM, et al. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest 2003;111:81-90. (Pubitemid 36134851)
14. Lam DC, Girard L, Ramirez R, Chau WS, Suen WS, Sheridan S, et al. Expression of nicotinic acetylcholine receptor subunit genes in nonsmall-cell lung cancer reveals differences between smokers and nonsmokers. Cancer Res 2007;67:4638-47. (Pubitemid 46910168)
15. Maneckjee R, Minna JD. Opioids induce while nicotine suppresses apoptosis in human lung cancer cells. Cell Growth Differ 1994;5:1033-40. (Pubitemid 24312278)
16. Davis R, Rizwani W, Banerjee S, Kovacs M, Haura E, Coppola D, et al. Nicotine promotes tumor growth and metastasis in mouse models of lung cancer. PLoS One 2009;4:e7524.
17. Dasgupta P, Rizwani W, Pillai S, Kinkade R, Kovacs M, Rastogi S, et al. Nicotine induces cell proliferation, invasion and epithelial-mesenchymal transition in a variety of human cancer cell lines. Int J Cancer 2009;124:36-45.
18. Catassi A, Servent D, Paleari L, Cesario A, Russo P. Multiple roles of nicotine on cell proliferation and inhibition of apoptosis: implications on lung carcinogenesis. Mutat Res 2008;659:221-31.
19. Chen RJ, Ho YS, Guo HR, Wang YJ. Long-term nicotine exposure-induced chemoresistance is mediated by activation of Stat3 and downregulation of ERK1/2 via nAChR and beta-adrenoceptors in human bladder cancer cells. Toxicol Sci 2010;115:118-30.
20. Fu XW, Lindstrom J, Spindel ER. Nicotine activates and up-regulates nicotinic acetylcholine receptors in bronchial epithelial cells. Am J Respir Cell Mol Biol 2009;41:93-9.
21. Spindel ER. Is nicotine the estrogen of lung cancer? Am J Respir Crit Care Med 2009;179:1081-2.
22. Murray RP, Connett JE, Zapawa LM. Does nicotine replacement therapy cause cancer? Evidence from the Lung Health Study. Nicotine Tob Res 2009;11:1076-82.
23. Hung RJ,McKay JD, Gaborieau V, Boffetta P, HashibeM, Zaridze D, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008;452:633-7. (Pubitemid 351483367)
24. Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008;452:638-42. (Pubitemid 351483366)
25. Amos CI, Wu X, Broderick P, Gorlov IP, Gu J, Eisen T, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 2008;40:616-22. (Pubitemid 351601203)
26. Murphy SE, von Weymarn LB, Schutten MM, Kassie F, Modiano JF. Chronic nicotine consumption does not influence 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone induced lung tumorigenesis. Cancer Prev Res 2011;4:1752-60.
27. Maier CR, Hollander MC,Hobbs EA, Dogan I, Dennis PA. Nicotine does not enhance tumorigenesis in mutant K-Ras-driven mouse models of lung cancer. Cancer Prev Res 2011;4:1743-51.
28. Peterson LA, Hecht SS. O6-methylguanine is a critical determinant of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone tumorigenesis in A/J mouse lung. Cancer Res 1991;51:5557-64.
29. Foulds J. The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline. Int J Clin Pract 2006;60:571-6.
30. Eisenberg MJ, Filion KB, Yavin D, Belisle P, Mottillo S, Joseph L, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ 2008;179:135-44. (Pubitemid 352020119)
31. Balfour DJ. The neurobiology of tobacco dependence: a preclinical perspective on the role of the dopamine projections to the nucleus accumbens [corrected]. Nicotine Tob Res 2004;6:899-912. (Pubitemid 40124750)
32. Tashkin DP, Murray RP. Smoking cessation in chronic obstructive pulmonary disease. Respir Med 2009;103:963-74.
33. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005;48:3474-7. (Pubitemid 40664098)
34. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2011:CD006103.
35. Williams JM, Steinberg MB, Steinberg ML, Gandhi KK, Ulpe R, Foulds J. Varenicline for tobacco dependence: panacea or plight? Expert Opin Pharmacother 2011;12:1799-812.
36. Tapper AR, McKinney SL, Nashmi R, Schwarz J, Deshpande P, Labarca C, et al. Nicotine activation of alpha4*receptors: sufficient for reward, tolerance, and sensitization. Science 2004;306:1029-32. (Pubitemid 39482905)
37. Cohen C, Bergis OE, Galli F, Lochead AW, Jegham S, Biton B, et al. SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation. J Pharmacol Exp Ther 2003;306:407-20. (Pubitemid 36734399)
38. Escobar-Chavez JJ, Dominguez-Delgado CL, Rodriguez-Cruz IM. Targeting nicotine addiction: the possibility of a therapeutic vaccine. Drug Des Devel Ther 2011;5:211-24.
39. Cerny EH, Cerny T. Vaccines against nicotine. Hum Vaccin 2009;5:200-5.